Search Medical Condition
Please enter condition
Please choose location
Clear Trial Filters
 

Hepatitis Clinical Trials

A listing of Hepatitis medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

RESULTS

Found (60) clinical trials

Trends in Risk Factors for Mother-to-Child Transmission of Hepatitis C Among a Southern European Population

Materials and Methods: This multi-centre epidemiological study (CHU Nice, CHU Toulouse, CHU Montpellier, H Clinic Barcelona, H Mar Barcelona) consists in two parts. Our study does not interfere with the usual management of mother and child as laboratory data (virology, immunology, and liver function) are already included in the medical ...

Phase N/A

A Study of Molecular and Genetic Factors for Liver Cancer in the Greater Baltimore Area

BACKGROUND: Liver cancer is the third most deadly and fifth most common cancer worldwide. Hepatocellular carcinoma (HCC) is the most frequent primary cancer of the liver with rising incidence in the United States. HCC patients have a dismal outcome and are an underserved cancer population. We are proposing a liver ...

Phase N/A

The Pathogenesis of Hepatitis C Virus Vertical Transmission

To evaluate for the presence of HCV Core protein, HCV RNA and SPP in the placenta and fetal membranes using paraffin-embedded sections and post-delivery specimens respectively. In parallel, we will assess placental tissue for evidence of HCV infection using a novel in situ hybridization technique and translate our in vitro ...

Phase N/A

Be the Bridge Between Researchers and a Cure (GVHD ALS Hepatitis B Alzheimer's Disease Leukemia and More)

This study will collect blood and other optionally donated tissue samples from people with all different types of health conditions, as well as healthy control samples, in order to provide biomedical researchers with quality biospecimens that are necessary in translating basic science research into clinically relevant information and technology.

Phase N/A

Therapeutic Option for Hepatitis B and C: a French Cohort

General schedule of the study : - Prospective multicenter national study - Duration of inclusions:3 years - Effective : 25000 patients - Duration of the follow-up: 7-8 years - Duration of the cohort: 10 years Population : Twenty-five thousands of people will be included and followed in investigator sites, 15000 ...

Phase N/A

Evaluation of Patients With Liver Disease

This is a general clinical research protocol to allow for evaluation, investigation and long-term follow up of patients who have an acute or chronic liver disease. The protocol is designed to study the natural history and pathogenesis of various liver diseases such as acute and chronic hepatitis B, C, D ...

Phase N/A

Epidemiology Infectivity and Natural History of Hepatitis C Virus Infection

At initiation of this study in 1991, approximately 0.6% of U.S. blood donors were identified as having antibody to the hepatitis C virus (anti-HCV). This represented 72,000 of the estimated 12 million annual U.S. blood donations. By investigating a cohort of anti-HCV positive donors, this study aims to determine: 1) ...

Phase N/A

Prevalence of Hepatitis B in Vall s Occidental. Observational Multicentric Study

The hepatitis B virus ( HBV ) is a global health problem . It is estimated that in the world there are about 350-400 million carriers of HBV surface antigen ( HBsAg ) 1 . The prevalence in Spain is estimated at a 2-7 % and is considered a second ...

Phase N/A

Racial Difference in HCV/Host Interactions

The University of Tennessee Health Science Center (UTHSC) Memphis Hepatitis C Cooperative Research Center was established in 2000 to support clinical and basic research in understanding the basis for chronic disease in hepatitis C (HCV) infection and response to therapy in clinically infected patients. The primary research goal is to ...

Phase N/A

Drug-Induced Liver Injury (DILN)Network Retrospective

Drug-induced liver injury (DILI) is the single most common reason for regulatory actions concerning drugs, including failure to gain approval for marketing, removal from the market place, and restriction of prescribing indications. DILI is also a significant cause of morbidity and mortality in many patient populations. To stimulate and facilitate ...

Phase N/A